RAS Dialogue Blog
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
MAP2K4: New kid on the MAP Kinase block
Post-doc Robin A Jansen and her advisor Rene Bernards lay out a compelling argument for MAP2K4 inhibition as an effective combination therapy with RAS-targeted drugs.
-
Development of Mutant KRAS Molecuar Target Drugs and Future Prospects: Report
In a new post, Drs. Fuyuhiko Tamanoi, Hideyuki Saya, Toshio Imai, and Kiyoko Kato present a report of the online meeting that they organized, titled “Development of mutant KRAS molecular target drugs and future prospects.”
-
Senescent macrophages promote oncogenic KRAS-driven lung cancer and suppress anti-tumour immunity
Drs. Haston, Muñoz-Espin, and Martinez-Barbera describe their work uncovering the important role that senescent macrophages play in promoting KRAS-driven lung cancers.
-
Inhibition of the MAPK pathway induces re-localization of membranous proteins, leading to adaptive resistance to KRAS G12C inhibitor mediated by YAP-induced MRAS
Yuta Adachi and Hiromichi Ebi describe their work uncovering a non-genetic resistance mechanism to KRAS G12C inhibitors involving the mis-localization of scribble, which induces YAP-mediated MRAS expression and reactivates MAPK signaling.